Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

Area of Science:

• Clinical Medicine
• Infectious Diseases
• Pharmacology

Background:

• Colchicine, an anti-inflammatory drug, has been investigated as a potential treatment for COVID-19.
• The need for effective community-based treatments for COVID-19 remains critical.

Purpose of the Study:

• To evaluate the efficacy of colchicine in accelerating recovery from COVID-19.
• To assess colchicine's impact on reducing hospital admissions and deaths in community-based COVID-19 patients.

Main Methods:

• A prospective, multicentre, randomized, controlled, adaptive platform trial (PRINCIPLE) was conducted.
• Adults with suspected COVID-19 and at higher risk of complications were randomized to receive usual care plus colchicine or usual care alone.
• Co-primary endpoints included time to recovery and COVID-19-related hospital admissions/deaths within 28 days.

Main Results:

• Time to self-reported recovery was similar between the colchicine and usual care groups, with a median increase of 1.4 days for colchicine.
• The probability of meaningful benefit in recovery time was very low (1.8%).
• COVID-19-related hospital admissions or deaths were comparable between the colchicine and usual care groups.

Conclusions:

• Colchicine treatment did not demonstrate a significant benefit in improving recovery time for community-dwelling individuals with COVID-19.
• The drug showed no significant effect on reducing hospitalizations or mortality related to COVID-19 in this high-risk population.